We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $5.12B
1-Year Est. Return 314.02%
This Fund
S&P 500
This Quarter Est. Return
+41.65%
1 Year Est. Return
+314.02%
3 Year Est. Return
+1,498.66%
5 Year Est. Return
+2,457.67%
10 Year Est. Return
+48,821.41%
AUM
$6.17B
AUM Growth
+$2.33B
Cap. Flow
+$258M
Cap. Flow %
4.18%
Top 10 Hldgs %
45.67%
Holding
151
New
35
Increased
25
Reduced
17
Closed
26

Top Buys

Rank Stock Value
1
FMTX
Forma Therapeutics Holdings, Inc. Common Stock
FMTX
+$54.2M
2
LYRA
LYRA THERAPEUTICS INC
LYRA
+$47.1M
3
ZNTL icon
Zentalis Pharmaceuticals
ZNTL
+$40.3M
4
ZGNX
Zogenix, Inc.
ZGNX
+$40.1M
5
FUSN
Fusion Pharmaceuticals Inc. Common Shares
FUSN
+$38.9M

Top Sells

Rank Stock Value
1
NBIX icon
Neurocrine Biosciences
NBIX
+$102M
2
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$53.2M
3
REGN icon
Regeneron Pharmaceuticals
REGN
+$36.9M
4
TBPH icon
Theravance Biopharma
TBPH
+$23.1M
5
NVRO
NEVRO CORP.
NVRO
+$22.8M

Sector Composition

Rank Sector Weight
1 Healthcare 82.05%
2 Financials 0.28%
3 Materials 0.1%
4 Technology 0.1%
5 Consumer Discretionary 0.02%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RVNC
101
DELISTED
Revance Therapeutics, Inc.
RVNC
$1.61M 0.03%
65,839
-859,161
-93% -$17M
DVAX
102
DELISTED
Dynavax Technologies
DVAX
$1.57M 0.03%
+176,950
New +$894K
EIGR
103
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
$1.34M 0.02%
4,663
– –
LEGN icon
104
Legend Biotech
LEGN
$3.64B
$1.06M 0.02%
+25,000
New +$977K
RACE icon
105
Ferrari
RACE
$67.9B
$1.06M 0.02%
6,200
– –
LVGO
106
DELISTED
Livongo Health, Inc. Common Stock
LVGO
$1.02M 0.02%
+13,620
New +$713K
MNTA
107
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
$1.02M 0.02%
30,637
– –
TRIL
108
DELISTED
Trillium Therapeutics Inc.
TRIL
$928K 0.02%
+114,674
New +$709K
SRRA
109
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
$807K 0.01%
66,655
+1
+0% +$12
KRTX
110
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
$774K 0.01%
6,944
– –
AKBA icon
111
Akebia Therapeutics
AKBA
$335M
$716K 0.01%
+52,724
New +$545K
KRMD icon
112
KORU Medical Systems
KRMD
$186M
$672K 0.01%
74,813
– –
CUE icon
113
Cue Biopharma
CUE
$120M
$646K 0.01%
879
– –
LMNX
114
DELISTED
Luminex Corp
LMNX
$616K 0.01%
+18,926
New +$599K
CCXI
115
DELISTED
ChemoCentryx, Inc.
CCXI
$590K 0.01%
10,252
– –
TGTX icon
116
TG Therapeutics
TGTX
$8.15B
$580K 0.01%
+29,762
New +$479K
VIR icon
117
Vir Biotechnology
VIR
$1.45B
$534K 0.01%
+13,024
New +$437K
APLS
118
DELISTED
Apellis Pharmaceuticals
APLS
$373K 0.01%
11,418
– –
AVDL
119
DELISTED
Avadel Pharmaceuticals
AVDL
$133K ﹤0.01%
8,681
– –
OTLKW
120
DELISTED
Outlook Therapeutics, Inc. Series A Warrant Expiring 02/18/2022
OTLKW
$108K ﹤0.01%
420,875
– –
ABEO icon
121
Abeona Therapeutics
ABEO
$340M
– –
-60,000
Closed -$3.06M
ACET icon
122
Adicet Bio
ACET
$76.1M
– –
-83
Closed -$10K
ANAB icon
123
AnaptysBio
ANAB
$1.53B
– –
-500,000
Closed -$7.07M
DNLI icon
124
Denali Therapeutics
DNLI
$3.76B
– –
-850,000
Closed -$14.9M
GILD icon
125
Gilead Sciences
GILD
$166B
– –
-1,500,000
Closed -$11.2M
2 3 4
5
6

Similar funds

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
TAM
Todd Asset Management Louisville, Kentucky $5.11B AUM 34.73% 1-Year Est. Return
CIA
Choate Investment Advisors Boston, Massachusetts $5.11B AUM 17.2% 1-Year Est. Return
AC
AKO Capital London, United Kingdom $5.11B AUM 2.56% 1-Year Est. Return
EIC
Equity Investment Corp Atlanta, Georgia $5.11B AUM 8.63% 1-Year Est. Return
CIC
Carnegie Investment Counsel Pepper Pike, Ohio $5.13B AUM 22.98% 1-Year Est. Return
CS
Cannell & Spears New York $5.1B AUM 31.77% 1-Year Est. Return
NC
Nicholas Company Milwaukee, Wisconsin $5.1B AUM 8.43% 1-Year Est. Return

Perceptive Advisors's Q2 2020 Portfolio in Review

As of Q2 2020, Perceptive Advisors held 151 positions worth $6.17B, up 61% from $3.84B the previous quarter. Its ten largest holdings account for 46% of the portfolio.

Perceptive Advisors deployed $258M of net new capital in Q2 2020, opening 35 new positions and adding to 25 existing holdings. Its largest new stake was Forma Therapeutics Holdings, Inc. Common Stock: 1,250,000 shares worth $58.1M.

By sector, the portfolio is most concentrated in Healthcare at 82% of assets, down from 95% a quarter earlier, followed by Financials and Materials.

On the sell side, the largest reduction was Neurocrine Biosciences, an estimated $102M trimmed.

  • Perceptive Advisors's largest Q2 2020 buy was Forma Therapeutics Holdings, Inc. Common Stock: 1,250,000 shares worth $58.1M.
  • Perceptive Advisors added most to Zogenix, Inc. in Q2 2020, an estimated $40.1M increase.
  • Perceptive Advisors's biggest Q2 2020 reduction was Neurocrine Biosciences, cutting an estimated $102M.
  • Perceptive Advisors fully exited Theravance Biopharma in Q2 2020, selling an estimated $23.1M.
  • Perceptive Advisors's ten largest holdings make up 46% of its $6.17B portfolio in Q2 2020.
  • Perceptive Advisors opened 35 new positions and closed 26 in Q2 2020.
  • Perceptive Advisors's portfolio value rose 61% quarter-over-quarter to $6.17B.

Based on Perceptive Advisors's 13F filing for Q2 2020, filed 14 Aug 2020.